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Any structural genomics endeavor, particularly ambitious ones such as the
NIAID-funded Seattle Structural Genomics Center for Infectious Disease
(SSGCID) and Center for Structural Genomics of Infectious Disease (CSGID),
face technical challenges at all points of the production pipeline. One salvage
strategy employed by SSGCID is combined gene engineering and structure-
guided construct design to overcome challenges at the levels of protein
expression and protein crystallization. Multiple constructs of each target are
cloned in parallel using Polymerase Incomplete Primer Extension cloning and
small-scale expressions of these are rapidly analyzed by capillary electrophor-
esis. Using the methods reported here, which have proven particularly useful for
high-value targets, otherwise intractable targets can be resolved.
1. Introduction
The Seattle Structural Genomics Center for Infectious Disease
(SSGCID) was established as a collaboration between Seattle
BioMed, Emerald BioStructures and the University of Washington in
2007. The primary mission of SSGCID is to establish a resource for
gene-to-structure research focused on the structure determination of
400 protein targets from NIAID Category A–C pathogens, as well
as organisms causing emerging and re-emerging infectious diseases
(Myler et al., 2009). To accomplish this, the SSGCID consortium
has adapted a multipronged serially escalating approach to protein-
structure solution. As shown in Fig. 1, the SSGCID production
pipeline has been outﬁtted with several technological layers, referred
to as ‘Tiers’, which can be applied as salvage strategies. In Tier 1
(upper left corner, progressing from top to bottom), targets are
cloned from native sources and protein expression is attempted in a
bacterial host. In Tier 2, target genes are subcloned from Tier 1
constructs into the appropriate expression vector for wheat germ cell-
free protein expression.
In Tier 3, the native genes are abandoned and all genes are engi-
neered using Gene Composer (Raymond et al., 2009; Lorimer et al.,
2009). Synthetic genes are cloned via Polymerase Incomplete Primer
Extension (PIPE) cloning (Klock et al., 2008) into a T7-based
protein-expression vector engineered to donate an amino-terminal
hexahistidine-Smt fusion and are expressed in bacterial cells. Soluble
protein production from each of the six constructs per target is
assessed by small-volume protein-expression testing, measuring the
amount of recombinant protein partially puriﬁed by batch IMAC
using magnetic nickel beads (Gaberc-Porekar & Menart, 2001). All
promising constructs of all targets are then grown as large-scale
expression cultures in a LEX bioreactor.
Being a gene-to-structure service for the community at large is the
key mission of SSGCID and direct requests from the community
are treated as high-value targets. Tier 3 can be utilized as a salvage
strategy for any targets that have failed to produce sufﬁcient soluble
protein in Tiers 1 and 2. Moreover, Tier 3 also serves as an efﬁcient
entry point to the SSGCID pipeline for eukaryotic/viral community
request targets or any target for which the requestor has failed to
produce soluble protein in the bacterial platform. Here, we describe
the gene design, cloning and protein-expression methodologies forhigh-value SSGCID targets and summarize the utility of these
methods in our consortium.
2. Materials and methods
2.1. Target gene engineering
All gene-engineering steps were undertaken using Gene Composer
software (Lorimer et al., 2009; Raymond et al., 2009). The design
process began with the full-length target amino-acid sequence, which
was backtranslated to allow codon harmonization with the bacterial
expression host. Brieﬂy, an Escherichia coli codon-utilization table
was applied to dictate the frequency with which synonymous codons
are used to encode the target protein, with a minimum frequency
of 2% required for inclusion. Many additional engineering steps
followed, including secondary-structure minimization, G:C content
balance, removal of cryptic Shine–Delgarno sequences, addition of
second- and third-frame ambush stop codons, relieving extended
nucleotide or codon repeats and introduction or removal of restric-
tion sites. All nucleic acid modiﬁcations were made without modiﬁ-
cation of the intended amino-acid sequence.
Once a nucleic acid sequence had been derived through engi-
neering, alternative protein constructs were designed. The design
session aligned the primary structure of the target protein with
homologous proteins from the Protein Data Bank (PDB), including
all secondary-structure and contact information derived from the
PDB ﬁles. New protein termini were selected based on conservation
of primary structure, secondary structure and structure resolution
information. In this way, ﬁve alternative constructs were designed
with the beneﬁt of all that is known about homologous structures.
This strategy is a proven technique to improve crystallization and
structure-solution rates (Gra ¨slund et al., 2008). Example constructs
are schematized as gold bars in Fig. 2(a). The engineered gene
encoding the full-length protein was purchased from a synthesis
vendor and this one synthetic gene served as a template for cloning
the full-length and terminal truncation variants.
2.2. Cloning
All clones were produced using PIPE cloning. This is a PCR-based
cloning strategy which requires no enzymes beyond the PCR poly-
merase and allows the cloning of crude PCR products without labor-
intensive product puriﬁcation. In this method, the target gene is
ampliﬁed in an ‘insert PCR reaction’ by primers with homology to
both the gene termini (25-base complementarity) as well as the vector
termini (15-base complementarity), while the vector is ampliﬁed in a
‘vector PCR reaction’ by primers with only vector complementarity.
PIPE cloning is schematized in Fig. 2(b); the insert and vector PCR
products are shown in Fig. 2(c). The vector for bacterially expressed
targets in this SSGCID Tier was a T7-based expression vector which
had been engineered to donate an amino-terminal hexahistidine-Smt
tag (MGHHHHHHSGEVKPEVKPETHINLKVSDGSSEIFFKIK-
KTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQTP-
EDLDMEDNDIIEAHREQIGG). The Smt tag is very speciﬁcally
and efﬁciently removed by UlpI protease, which recognizes the three-
dimensional fold of Smt rather than a short primary structure
(Mossessova & Lima, 2000). The digested target protein carries no
artifact from the tag, which may be an advantage for crystallographic
efforts. In this way, UlpI cleavage serves as a conﬁrmation that the
recombinant protein is soluble and properly folded. The PCR cycling
excluded the ﬁnal extension step, allowing the ﬁnal products to have
variably single-stranded termini, which is the necessary result of
incomplete primer extension. The crude insert PCR and crude vector
PCR reactions were combined in equal volumes and this combination
was transformed into chemically competent TOP10 cells. Annealing
of the complementary regions on the termini of the insert and vector
PCR products created the rare but selectable desired expression
plasmid. Two to four colonies were screened by DNA sequencing,
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Figure 1
SSGCID multipronged escalating pipeline. Each Tier can be read from top to bottom, with increasing technology applications read from left to right. Annual goal estimates
are tabulated on the right, with Tier-speciﬁc success rates calculated along the bottom.laboratory communications
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Figure 2
Tier3 gene design and cloning strategy. (a)Gene Composer design-session window,showing the target amino-acid base construct ingreen (middle window) and the structure-
guided construct-design products in gold (bottom window). (b) Polymerase Incomplete Primer Extension (PIPE) cloning strategy used for this tier of SSGCID pipeline
production. Insert PCR products are ampliﬁed using primers with homology to the vector termini (shown in red and blue). Vector PCR products are ampliﬁed by primers
with homology to only the vector termini. (c) Agarose-gel analysis of insert PCR (with target amino-acid numbering) and vector PCR products.generally resulting in an 85% cloning success rate. Failures pre-
dominantly occurred at the level of the insert PCR reaction, which
can be constrained by the thermodynamics of the terminal nucleotide
sequence.
2.3. Small-scale expression and expression testing
Sequence-veriﬁed clones were transformed into chemically com-
petent BL21 (DE3) cells for protein expression and stored as glycerol
stocks at 193 K. Glycerol stocks were streaked on selective agar and
freshly grown isolated colonies were used to inoculate 1.2 ml over-
night cultures of Terriﬁc Broth (TB) medium supplemented with
0.5% glucose. All small-scale cultures were grown in round-bottom
96-well blocks. This non-inducing culture was grown overnight at
298 K with shaking at 220 rev min
1. After approximately 16 h, 40 ml
of this overnight culture was used to inoculate 1.2 ml TB medium
supplemented with Overnight Express System 1 autoinduction
reagents (Novagen). Following inoculation, the 96-well block was
allowed to shake at 293 K for approximately 10 min to allow thor-
ough mixing. After mixing, the 1.2 ml culture was split into two 0.6 ml
cultures using an additional 96-well block. Small-scale induction
cultures were grown for 48 h at 293 K, shaking at 220 rev min
1.
Cultures were harvested by centrifugation and stored at 253 K for at
least 1 h prior to processing.
Frozen bacterial pellets were resuspended and lysed in 50 mM
NaH2PO4 pH 8, 300 mM NaCl, 10 mM imidazole, 1% Tween 20,
2m M MgCl2, 1 mg ml
1 lysozyme and 0.1 mlm l
1 Benzonase and
processed essentially as proscribed by the nickel-bead manufacturer
(Qiagen). Chemical lysis was allowed to proceed by 30 min of
vigorous shaking at room temperature. The crude lysate was clariﬁed
by centrifugation for 30 min at 4000 rev min
1 and 277 K.The soluble
fraction was combined with magnetic Ni–NTA beads in a V-bottom
microtiter plate and allowed to react for 1 h with shaking at 289 K.
The unbound soluble protein was removed and the magnetic nickel
beads were washed twice with 200 ml wash buffer: 50 mM NaH2PO4
pH 8, 300 mM NaCl, 20 mM imidazole and 0.05% Tween 20. The
washed proteins were eluted in 5 min with 60 ml elution buffer:
50 mM NaH2PO4 pH 8, 300 mM NaCl, 250 mM imidazole and 0.05%
Tween 20. A portion of each elution product was reacted with UlpI
protease for 30 min at room temperature. Both the untreated and
the protease-treated elution products were analyzed by capillary
electrophoresis in a LabChip 90 (Caliper), as shown in Fig. 3.
Alternatively, all fractions from the expression testing can be
analyzed by SDS–PAGE.
2.4. Large-scale expression
Inoculum cultures of TB medium supplemented with antibiotics
(50 mgm l
1 kanamycin) were grown for approximately 18 h at 310 K.
TB auto-induction medium was freshly prepared according to the
manufacturer’s protocol (Novagen) and was supplemented with
antibiotics. The bottles were inoculated with 3 ml overnight culture.
Inoculated bottles were placed into a LEX bioreactor (Harbinger
Biotech, Ontario, Canada). Cultures were grown for approximately
60–72 h at 293 K. To harvest, the culture was centrifuged at 4000g for
20 min at 277 K. A 10 ml aliquot of the culture was processed sepa-
rately and screened for total protein, soluble protein and the fraction
that binds to immobilized metal-afﬁnity chromatography (IMAC) to
predict which large-scale expressions were worth processing further
for puriﬁcation. Until that time, the cell paste was stored at 193 K.
2.5. Protein purification
All aspects of protein puriﬁcation are covered in detail in Smith et
al. (2011).
3. Results and discussion
The Seattle Structural Genomics Center for Infectious Disease
(SSGCID) is committed to and achieving the goal of determining
75–100 three-dimensional protein structures per year from NIAID
Category A–C and emerging/re-emerging infectious disease organ-
isms. SSGCID employs a high-throughput gene-to-structure pipeline
laboratory communications
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Figure 3
Analysis and quantitation of point-mutant recombinant proteins partially puriﬁed
on a small scale. (a) Virtual gel of capillary electrophoresis by Caliper LapChip 90.
Yields vary by mutant. (b) Mutant speciﬁc protein yields obtained, with wild-type
protein indicated by a red arrow.
Figure 4
Protein crystal of polymerase PB2 subunit from 2009 pandemic inﬂuenza H1N1.involving a multi-pronged serial escalation approach to protein
expression in bacterial, wheat germ cell-free translation, baculovirus
and mammalian systems followed by structure solution using X-ray
crystallography and NMR spectroscopy. Proactive engagement of the
infectious disease research and drug-therapy communities in the
target-selection process helps to ensure that the resulting protein
structures provide a blueprint for structure-based drug design of new
therapeutics to combat infectious diseases. Moreover, the SSGICD
laboratory communications
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Table 1
Outcome analysis for inﬂuenza polymerase targets processed by the methods described here from a variety of viral strains.
Each subunit of the heterotrimeric polymerase from each strain is treated as a separate target (with SSGCID identiﬁer given), for which 2–7 structure-guided terminal truncation
constructs were designed. The structure-determination pipeline is broken down into ﬁve distinct steps: cloning, solubility testing, protein puriﬁcation, protein crystal formation and
structure solution. Percentage success overall is calculated by target to account for the multiple constructs designed for each target; percentage success per step is calculated by construct.
Strain Polymerase subunit Target Constructs Cloned Soluble Puriﬁed Crystals Structure
Avian-1023 H5N1 PB2 InvaA.07055.a 7 7 3 3 2 2
PB1 InvaA.07056.a 2 2 0 0 0 0
PA InvaA.07057.a 6 6 2 2 1 0
Avian-2017 H2N3 PB2 InvaB.07055.c 7 7 2 2 2 1
PB1 InvaB.07056.c 2 2 0 0 0 0
PA InvaB.07057.c 6 6 0 0 0 0
Equine-1 H7N7 PB2 InvaC.07055.b 7 7 3 3 3 0
PB1 InvaC.07056.b 2 2 1 1 0 0
PA InvaC.07057.b 6 6 2 2 0 0
Swine-04 H1N1 PB2 InvaD.07055.a 7 5 3 3 1 1
PB1 InvaD.07056.a 2 2 0 0 0 0
PA InvaD.07056.a 5 5 4 4 1 0
Swine-InDRE4487 H1N1 PB2 InvaE.07055.a 6 6 3 3 1 1
PA InvaE.07057.a 5 5 2 2 0 0
Swine-05 H1N1 PA InvaF.07057.a 4 4 3 3 0 0
Total 15 74 72 28 28 11 5
Overall success (%) 100 73 73 47 27
Success per step (%) 97 39 100 39 45
Figure 5
Protein structures of inﬂuenza polymerase subunit PB2 from a variety of viral strains obtained using the methods described in this publication. PDB codes (clockwise from
top left): 3r2v (T. E. Edwards, A. S. Gardberg & B. Sankaran, unpublished work), 3kc6 (Yamada et al., 2010), 3l56 (Yamada et al., 2010) and 3khw (Yamada et al., 2010).pipeline serves as a gene-to-structure service for the community at
large.
Community-requested targets are considered to be particularly
high-value targets. Where appropriate, these targets are processed
through Tier 3 of the escalating pipeline, which is the focus of this
report. The majority of the structures are solved either as apoproteins
or as complexes with native ligand. In some cases, however, high-
value targets are pursued as binary ligand complexes as a means to
further inform drug-design and discovery efforts. Fragment screening
can introduce an additional level of challenge. The target protein
must not only form high-resolution crystals which can be solved, but
the crystal form must also be amenable to soaking with the compound
library. One such case is highlighted in Fig. 3, in which the target is
readily crystallizable but a different crystal form is sought.
In addition to our internally selected and community-requested
targets, the methods reported here have also enabled a rapid
response to emerging diseases such as the 2009 pandemic inﬂuenza
H1N1 (Yamada et al., 2010). Example protein crystals of inﬂuenza
polymerase PB2 subunit are shown in Fig. 4 and a panel of inﬂuenza
structures deposited in the Protein Data Bank (PDB) as a result of
these methods are highlighted in Fig. 5. An outcome analysis focused
on the SSGCID inﬂuenza targets is shown in Table 1, which reports
the success of each target at each step and the overall success rates
resulting from the use of these Tier 3 methods. Judicious use of the
Tier 3 methodology has enabled efﬁcient production and evaluation
of alternative constructs, which in turn accelerates our structure-
solution pipeline.
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